Literature DB >> 11093454

Responsiveness of fibromyalgia clinical trial outcome measures.

P R Dunkl1, A G Taylor, G G McConnell, A P Alfano, M R Conaway.   

Abstract

OBJECTIVE: To assess the responsiveness of the Fibromyalgia Impact Questionnaire (FIQ), patient ratings of pain intensity, number of tender points, and total tender point pain intensity score to perceived changes in clinical status in patients with fibromyalgia (FM).
METHODS: Using data from a randomized placebo controlled study evaluating efficacy of magnetic therapy in patients with FM, the ability of primary outcomes to detect clinically meaningful changes over a 6 month period was assessed by: (1) degree of association between outcome change scores and patient global ratings of symptom change (Spearman rank-order correlations); (2) ability of these scores to discriminate among groups of patients whose perceived health status had changed to varying degrees (ANOVA); (3) ability of these scores, individually and jointly, to discriminate between patients who had reported improvement and those who did not (logistic regression); (4) effect size, standardized response mean, and Guyatt's statistic were calculated to quantify responsiveness.
RESULTS: Correlations showed the outcome measures were moderately responsive to perceived symptomatic change. For FIQ, pain intensity ratings and number of tender points, differences in change scores between globally improved and unchanged groups and between globally improved and worsened groups were significant; for total tender point pain intensity, the globally improved differed from worsened group. FIQ outperformed the other measures in discriminating between patients who reported improvement from those who did not. Summary statistics were consistent with discriminatory analyses, indicating the measures were sensitive to improvement, but relatively unresponsive to decline.
CONCLUSION: The FIQ was the most responsive measure to perceived clinical improvement and we recommend its inclusion as a primary endpoint in FM clinical trials.

Entities:  

Mesh:

Year:  2000        PMID: 11093454

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  34 in total

1.  Development of responder definitions for fibromyalgia clinical trials.

Authors:  Lesley M Arnold; David A Williams; James I Hudson; Susan A Martin; Daniel J Clauw; Leslie J Crofford; Fujun Wang; Birol Emir; Chinglin Lai; Rong Zablocki; Philip J Mease
Journal:  Arthritis Rheum       Date:  2012-03

2.  Is psychological distress intrinsic to fibromyalgia syndrome? Cross-sectional analysis in two clinical presentations.

Authors:  Monika Salgueiro; Zigor Aira; Itsaso Buesa; Juan Bilbao; Jon Jatsu Azkue
Journal:  Rheumatol Int       Date:  2011-11-08       Impact factor: 2.631

3.  The health effects of at-home written emotional disclosure in fibromyalgia: a randomized trial.

Authors:  Mazy E Gillis; Mark A Lumley; Angelia Mosley-Williams; James C C Leisen; Timothy Roehrs
Journal:  Ann Behav Med       Date:  2006-10

Review 4.  Pregabalin: a review of its use in fibromyalgia.

Authors:  Katherine A Lyseng-Williamson; M Asif A Siddiqui
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  The relationship between tender point count and disease severity in patients with primary fibromyalgia.

Authors:  Ali Salli; Halim Yilmaz; Hatice Ugurlu
Journal:  Rheumatol Int       Date:  2010-07-30       Impact factor: 2.631

6.  Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment.

Authors:  Adam R Burkey; Peter A Kanetsky
Journal:  J Pain Symptom Manage       Date:  2008-12-06       Impact factor: 3.612

7.  The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties.

Authors:  Robert M Bennett; Ronald Friend; Kim D Jones; Rachel Ward; Bobby K Han; Rebecca L Ross
Journal:  Arthritis Res Ther       Date:  2009-08-10       Impact factor: 5.156

8.  Toward characterization and definition of fibromyalgia severity.

Authors:  Stuart Silverman; Alesia Sadosky; Chris Evans; Yating Yeh; Jose Ma J Alvir; Gergana Zlateva
Journal:  BMC Musculoskelet Disord       Date:  2010-04-08       Impact factor: 2.362

9.  Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect.

Authors:  Fausto Salaffi; Piercarlo Sarzi-Puttini; Rita Girolimetti; Stefania Gasparini; Fabiola Atzeni; Walter Grassi
Journal:  Arthritis Res Ther       Date:  2009-08-18       Impact factor: 5.156

10.  The feasibility and efficacy of a multidisciplinary intervention with aftercare meetings for fibromyalgia.

Authors:  Mariëlle Kroese; Guy Schulpen; Monique Bessems; Frans Nijhuis; Johan Severens; Robert Landewé
Journal:  Clin Rheumatol       Date:  2009-05-05       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.